Synthegenix Pharmaceuticals is categorized under Commercial Medical Research in Medford, MA and active since 2012.
Synthegenix Pharmaceuticals was established in 2012, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Sergey Nikolenko at the company’s single location by writing to 55 Station Landing Apartment 336, Medford, Massachusetts MA 02155 or by phoning (857) 222-8544. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Synthegenix Pharmaceuticals |
| Contact Person: | Sergey Nikolenko |
| Address: | 55 Station Landing Apartment 336, Medford, Massachusetts 02155 |
| Phone Number: | (857) 222-8544 |
| Annual Revenue (USD): | $50.000 to $99.999 |
| Founded: | 2012 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Synthegenix Pharmaceuticals was started in 2012 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.
Feel free to contact Sergey Nikolenko for inquiries that concern Synthegenix Pharmaceuticals by calling the company number (857) 222-8544, as your correspondence is most welcome. Additionally, the physical location of the single location of Synthegenix Pharmaceuticals can be found at the coordinates 42.403871,-71.080809 as well as the street address 55 Station Landing Apartment 336 in Medford, Massachusetts 02155.
For its online presence, you may visit Synthegenix Pharmaceuticals’s website at and engage with its social media outlets through on Twitter and on Facebook.